Document Detail

Subgroups of Graves' patients identified on the basis of the biochemical activities of their immunoglobulins.
MedLine Citation:
PMID:  7673424     Owner:  NLM     Status:  MEDLINE    
Graves' patient immunoglobulins (IgG) are known to activate adenylyl cyclase. Recently, we have shown that they also stimulate phospholipase A2 (PLA2). Here we analyze the relationship of these biochemical activities of Graves' IgG to thyroid growth in vitro ([3H]thymidine incorporation) and in vivo (patient goiter size) as well as to clinical indicators of severity of the disease, such as ophthalmopathy, T3 levels, T3/T4 molar ratio, and TSH binding-inhibiting IgG activity. A cluster analysis of the biochemical parameters referring to the whole population (158 subjects) led to the identification of 4 subgroups of Graves' patients based on the different capabilities of IgG to stimulate adenylyl cyclase, PLA2, and [3H]thymidine incorporation. Importantly, a trend of increasing severity of the disease from group 1 to group 4 could be identified. In particular, patients in group 4 (characterized by elevated stimulation of adenylyl cyclase, PLA2, and [3H]thymidine incorporation) had the largest goiter, highest serum concentration of T3, highest T3/T4 molar ratio, and highest prevalence of ophthalmopathy. These results indicate that Graves' IgG induce thyroid growth by stimulating both adenylyl cyclase and PLA2, and suggest a method for the subclassification of Graves' patients that identifies four groups with different degrees of severity of the disease. Moreover, this classification might lead to the targeted use of a novel therapeutic approach based on the inhibition of PLA2 and arachidonic acid metabolism.
A Di Cerbo; R Di Paola; M Bonati; M Zingrillo; V De Filippis; D Corda
Related Documents :
8596134 - Late effects of chemoradiotherapy in pediatric hodgkin's disease.
8307114 - Increased serum neopterin levels in patients with graves' disease.
10406404 - The use of oral pilocarpine in xerostomia and sjögren's syndrome.
9435414 - Outcome of thyroid function in graves' patients treated with radioiodine: role of thyro...
19413184 - Biocompatible peritoneal dialysis solutions: do they indeed affect the outcome?
2218894 - Intraoperative parathormone level measurement in the management of hyperparathyroidism.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  80     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1995 Sep 
Date Detail:
Created Date:  1995-10-17     Completed Date:  1995-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2785-90     Citation Subset:  AIM; IM    
Istituto di Ricerche Farmacologiche, Mario Negri, Consorzio Mario Negri Sud, Laboratory of Cellular and Molecular Endocrinology, Santa Maria Imbaro (Chieti), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arachidonic Acid / metabolism,  physiology
Cyclic AMP / metabolism
Graves Disease / blood*,  classification,  physiopathology
Immunoglobulin G / physiology*
Middle Aged
Thymidine / metabolism
Thyroid Gland / growth & development
Reg. No./Substance:
0/Immunoglobulin G; 50-89-5/Thymidine; 506-32-1/Arachidonic Acid; 60-92-4/Cyclic AMP

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal...
Next Document:  Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdomina...